Skip to main content

Table 3 The value of the liver, kidney, and tumor markers before and at the sixth month [mean ± SD or median (Q25–Q75)]

From: Efficacy and safety of umbilical cord mesenchymal stem cells in treatment of cesarean section skin scars: a randomized clinical trial

 

Baseline

Sixth month

All participants

Placebo group

Low-dose group

High-dose group

All participants

Placebo group

Low-dose group

High-dose group

ALT

9.72 ± 3.60

10.17 ± 4.04

9.63 ± 3.12

9.37 ± 3.65

16.82 ± 12.70

17.05 ± 9.97

17.09 ± 17.67

16.13 ± 6.54

AST

15.48 ± 3.40

15.93 ± 3.18

15.30 ± 3.04

15.20 ± 3.96

17.37 ± 6.34

16.62 ± 5.08

17.78 ± 7.94

17.75 ± 5.48

UA

345.58 ± 89.29

342.90 ± 83.96

328.40 ± 88.22

365.43 ± 94.42

333.10 ± 70.49

322.52 ± 62.01

343.48 ± 80.41

332.06 ± 67.91

BUN

3.77 ± 2.63

4.03 ± 4.42

3.61 ± 0.82

3.66 ± 0.93

4.65 ± 1.15

4.61 ± 1.01

4.74 ± 0.99

4.57 ± 1.55

CA125

19.63 (15.21–26.75)

19.62 (15.19–25.54)

19.36 (14.65–30.49)

20.75 (15.36–31.66)

15.13 (9.87–19.72)

15.85 (9.65–20.39)

13.18 (9.07–18.53)

15.13 (9.45–22.67)

CA153

13.21 (10.56–16.07)

13.20 (10.70–16.87)

12.81 (10.78–16.32)

13.39 (9.68–15.76)

8.62 (6.55–12.30)

7.52 (6.27–11.86)

8.89 (6.41–12.44)

10.49 (7.33–12.44)

CA199

9.54 (6.91–14.48)

9.29 (6.38–15.42)

8.66 (7.03–19.38)

10.27 (7.03–14.47)

9.11 (6.48–14.45)

10.58 (6.13–15.45)

7.53 (6.53–15.76)

10.78 (6.42–14.13)

CEA

0.62 (0.31–0.87)

0.70 (0.30–0.85)

0.60 (0.38–0.90)

0.61 (0.21–0.83)

0.84 (0.53–1.48)

1.21 (0.54–1.59)

0.66 (0.51–1.39)

0.79 (0.60–1.38)

  1. ALT alanine aminotransferase, AST aspartate aminotransferase, BUN blood urea nitrogen, CA125 cancer antigen 125, CA153 carbohydrate antigen 153, CA199 carbohydrate antigen 199, CEA carcinoembryonic antigen, UA uric acid